After participating in this educational activity, attendees should be able to:
1. Discuss the role of glutamatergic pathways in the treatment of depression
2. Review current evidence regarding the mechanism of action of ketamine and esketamine
3. Describe current state of evidence from clinical trials regarding safety and effectiveness of esketamine in the treatment of depression
4. Consider implications of ketamine research on current clinical practice
Barry Sarvet, MD
Professor of Medicine
University of Massachusetts Medical School-Baystate
Department of Psychiatry
Baystate Medical Center
None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 BCIPE Instructional Hours
- 1.00 APA Psychologists American Psychological AssociationBaystate Health is approved by the American Psychological Association to sponsor continuing education for psychologists. Baystate Health maintains responsibility for this program and its content.
- 1.00 NASW Smith CE CreditsThis program was approved for 1.00 Continuing Education Credits by Smith College School for Social Work and assigned authorization number in accordance with Continuing Education Regulation 258 CMR, Category I, in the Commonwealth of Massachusetts
- 1.00 NBCCBaystate Health is an NBCC Approved Continuing Education Provider (ACEP™) and may offer NBCC approved clock hours for events that meet NBC requirements. The ACEP solely responsible for all aspects of the program.